Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Healey, Gareth D ^a   Lockridge, Jennifer A ^b   Zinnen, Shawn ^c   Hopkin, Julian M ^a   Richards, Ivan ^d   Walker, William ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b Lockridge Pharmaceutical Consulting LLC   (United States)

^c Zincyte Consulting   (United States)

^d Sunapten Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; SMALL INTERFERING RNA; STAT6 PROTEIN;

ADULT; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NOSE CAVITY; PROTEIN EXPRESSION; RAT; RESPIRATORY TRACT ALLERGY; SINGLE DRUG DOSE; UPREGULATION;

ADMINISTRATION, INTRANASAL; ALLERGENS; ANIMALS; ASTHMA; CACO-2 CELLS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HUMANS; LUNG; MALE; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT6 TRANSCRIPTION FACTOR; TISSUE DISTRIBUTION;

EID: 84896341989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090338     Document Type: Article

References (47)

1. Adams NP and Jones PW (2006) The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. 100: 1297-1306.
2. Frois C, Wu EQ, Ray S and Colice GL (2009) Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 31: 2779-2803.
3. Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, et al. (1998) Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 187: 1537-1542. (Pubitemid 28215412)
4. Kuperman DA and Schleimer RP (2008) Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med 8: 384-392.
5. Wills-Karp M (2004) Interleukin-13 in asthma pathogenesis. Immunol Rev 202: 175-190.
6. Izuhara K, Arima K, Kanaji S, Ohta S and Kanaji T (2006) IL-13: a promising therapeutic target for bronchial asthma. Curr Med Chem 13: 2291-2298. (Pubitemid 44184653)
7. Izuhara K, Shirakawa T, Adra CN, Hamasaki N and Hopkin JM (1999) Emerging therapeutic targets in allergy: IL-4Rα and Stat6. Emerging Therapeutic Targets 3: 381-389.
8. Oh CK, Geba GP and Molfino N (2010) Investigational therapeutics targeting the IL-4/IL-13/STAT6 pathway for the treatment of asthma. Eur Resp Rev 115.
9. Holgate ST (2007) The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 28: 248-251.
10. Kato A and Schleimer RP (2007) Beyond inflammation: epithelial cells are at the interface of innate and adaptive immunity. Current Opinion Immunol 19: 1-10.
11. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, et al. (2002) Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nature Med 8: 885-889.
12. Walker W, Healey GD and Hopkin JM (2009) RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology 127: 256-266.
13. Healey GD, Zinnen S, Lockridge JA, Richards I, Evans N, et al. (2010) Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: Characterisation and selection of candidates for pre-clinical development. J RNAi Gene Silencing 25: 401-410.
14. Finkelman FD and Wills-Karp M (2008) Usefulness and optimization of mouse models of allergic airway disease. J Allergy Clin Immunol 121: 603-606. (Pubitemid 351323871)
15. Holmes AM, Solari R and Holgate ST (2011) Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discovery Today 16: 659-670.
16. Wenzel S and Holgate ST (2006) The mouse trap: it still yields few answers in asthma. Am J Respir Crit Care Med 174: 1173-1176. (Pubitemid 44924815)
17. Braunstahl G-J (2009) United airways concept. What does it teach us about systemic inflammation in airways disease? Proc Am Thorac Soc 6: 652-654.
18. Murugan A, Prys-Ricard C and Calhoun WJ (2009) Biomarkers in asthma. Curr Opin Pulm Med 15: 12-18.
19. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, et al. (2010) Allergic rhinitis and its impact on asthma (ARIA) guidelines. 2010 revision. J Allergy Clin Immunol 126: 466-476.
20. Togias A (2003) Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 111: 1171-1183.
21. Healey GD, Evans N, Hopkin JM, Davies G and Walker W (2013) Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma. J Cell Mol Med 17: 356-364.
22. Scaggiante B, Dapas B, Farra R, Grassi M, Pozzato G, et al. (2011) Improving siRNA bio-distribution and minimizing side effects. Curr Drug Metabol 12: 11-23.
23. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: 2002-2007.
24. Hilgers AR, Conradi RA and Burton PS (1990) Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7: 902-910. (Pubitemid 20349761)
25. Neurkar MM, Burton PS and Borchardt RT (1996) The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarised efflux system. Pharm, Res 13: 528-534. (Pubitemid 26119054)
26. Chen C, Rizdon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
27. Volpe DA (2011) Drug permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem 16: 2063-2077.
28. Harkema JR, Carey SA and Wagner JG (2006) The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicologic Pathol 34: 252-269.
29. Bakhtiyari S, Haghani K, G B and Karimfar MH (2013) siRNA therapeutics in the treatment of diseases. Ther Deliv 4: 45-57.
30. Musacchio T and Torchilin VP (2013) siRNA delivery: from basics to therapeutic applications. Front Biosci 18: 58-79.
31. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir R, Elbashir S, et al. (2008) Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77: 225-231.
32. Czimmerer Z, Hulvely J, Simandi Z, Varallyay E, Havelda Z, et al. (2013) A versatile method to design stem-loop primer-based quantitative PCR assays for detecting small regulatory RNA molecules. PLoS One 8: e55168.
33. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
34. Rana TM (2007) Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8: 23-36.
35. Takahashi Y, Nishikawa M and Takakura Y (2009) Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev 61: 760-766.
36. Whitehead KA, Langer R and Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discovery 8: 129-138.
37. Grimm D (2009) Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 61: 672-703.
38. Wang J, Lu Z, Wientjes MG and Au JL (2010) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12: 492-503.
39. Clark KL, Hughes SA, Bulsara P, Coates J, Moores K, et al. (2013) Pharmacological Characterization of a Novel ENaCa siRNA (GSK2225745) With potential for the treatment of cystic fibrosis. Mol Ther Nucleic Acids 2: e65.
40. Merkel OM and Kissel T (2012) Nonviral pulmonary delivery of siRNA. Acc Chem Res 45: 961-970.
41. Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, et al. (2011) Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 19: 2163-2168.
42. Darcan-Nicolaisen Y, Meinicke H, Fels G, Hegend O, Haberland A, et al. (2009) Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J Immunol 182: 7501-7508.
43. Lively TN, Kossen K, Balhorn A, Koya T, Zinnen S, et al. (2008) Effect of chemically modified IL-13 short interfering RNA on development of airway hyperreseponsiveness in mice. J Allergy Clin Immunol 121: 88-94.
44. Dolovich MB and Dhand R (2011) Aerosol drug delivery: developments in device design and clinical use. Lancet 377: 1032-1045.
45. Bourdin A, Gras D, Vachier I and Chanez P (2009) Upper airway. 1. Allergic rhinitis and asthma: united disease through epithelial cells. Thorax 64: 999-1004.
46. Bousquet J, Vignola A.M. and Demoly P (2003) Links between rhinitis and asthma. Allergy 58: 691-706. (Pubitemid 36920456)
47. McCaskill J, Singhania R, Burgess M, Allavena R, Wu S, et al. (2013) Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol Ther Nucleic Acids 2: e96.